Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial
Authors
Discussion
Loading...
Member takes
Implication
Findings demonstrate erythropoiesis-stimulating agent outcomes and hematological response implications in lower-risk myelodysplastic syndromes.
Key Points
- To identify predictive biomarkers linked to hematological response and improved overall survival in patients receiving luspatercept vs erythropoiesis-stimulating agents.
- Analyzed 206 baseline parameters including cytomorphology, reticulocyte count, and molecular features.
- Conducted logistic and Cox univariate regression analyses to identify predictors of response and survival.
- Utilized stepwise regression to refine predictive variables for each treatment arm.
- Luspatercept significantly increased transfusion independence compared to ESA (60% vs 35%).
- Lower IPSS-M and higher alpha-2 macroglobulin were associated with improved hematological response in luspatercept.
- Shared predictive biomarkers included NT-proBNP and iron levels, notable for both treatment arms.
Cite This Study
Garcia‐Manero et al. (2025) studied this question.